New therapeutic approaches in glioblastomas;Nouvelles approches thérapeutiques des glioblastomes

Bulletin du Cancer

Volumn 92, Issue 4, 2005, Pages 355-359

  Carpentier, Antoine F ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Clinical trial; Glioblastoma; Treatment

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARMUSTINE; CC 1719; CRM 107; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; IMMUNOSTIMULATING AGENT; INTERLEUKIN 13; LOMUSTINE; LONAFARNIB; MARIMASTAT; OLIGONUCLEOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PRINOMASTAT; PROTEIN KINASE B; PROTEINASE INHIBITOR; PSEUDOMONAS TOXIN; RAF PROTEIN; RAS PROTEIN; SUNITINIB; SURAMIN; TEMOZOLOMIDE; TIPIFARNIB; TOXIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSMID; UNCLASSIFIED DRUG; VATALANIB; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

BLOOD BRAIN BARRIER; BRAIN TUMOR; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG TARGETING; EDEMA; FEVER; GLIOBLASTOMA; HUMAN; NEUROLOGIC DISEASE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THERMODYNAMICS; CHROMOSOME ABERRATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOTHERAPY; METHODOLOGY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 18344370678     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Knobbe CB, Merlo A, Reifenberger G. PTEN signaling in gliomas. Neurooncol 2002; 4: 196-211.
2. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001; 2: 120-9.
3. Raymond E, Brandes A, Van Oosterom A, Dittrich C, Fumoleau P, Coudert B, et al. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC NDDG/BTG Intergroup Study. ASCO Annual Meeting, New Orleans. 2004; [Abst. 1501].
4. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22: 133-42.
5. Raizer JJ, Abrey LE, Wen P, Cloughesy T, Robins IA, Fine HA, et al. A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant gliomas not on EIAEDs. ASCO Annual Meeting, New Orleans. 2004; [abst. 1502].
6. Chang, Kuhn J, Wen P. Phase II/pharmacokinetic study of CCI-779 in recurrent glioblastoma multiforme. Neurooncol 2003; 5: 349; [abst.].
7. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63: 2742-6.
8. Cloughesy TF, Kuhn J, Wen P. Phase II trial of R115777 (zarnestra) in patients with reccurent glioma not taking enzyme inducing antiepileptic drugs (EIAED) a NABTC report. Proc Annu Meet Am Soc Clin Oncol 2002; 21: 317; [abst.].
9. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002; 20: 1383-8.
10. Levine PA, Phuphaniich S, Glantz ML. Randomized phase II study of temozolomide with and without the metalloprotease inhibitor prinomastat in patients with glioblastoma multiforme following best surgery and radiation therapy. Proc Annu Meet Am Soc Clin Oncol 2002; 21: 100; [abst.].
11. Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000; 50: 121-37.
12. Fine HA, figure WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 708-15.
13. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003; 21: 2299-304.
14. Grossman SA, Phuphanich S, Lesser G, Rozental J, Grochow LB, Fisher J, et al. New Approaches to Brain Tumor Therapy CNS Consortium. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J Clin Oncol 2001; 19: 3260-6.
15. Reardon D, Friedman H, Yung WKA, Brada M, Conrad C, Provenzale J, et al. A phase I/II trial of PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). ASCO Annual Meeting, New Orleans. 2004; [abst. 1513].
16. Conrad C, Friedman H, Reardon D, Provenzale J, Jackson E, Serajuddin H, et al. A phase I/II trial of single-agent PTK 787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). ASCO Annual Meeting, New Orleans. 2004; [abst. 1512].
17. Nabors LB, Rosenfeld SS, Mikkelsen T. A phase I trial of EMD121974 for treatment of patients with reccurent malignant gliomas. Neurooncol 2002; 4: 373.
18. Weingart J, Markert J, Rosenblum M, Ram Z, Kunwar S, et al. Determination of toxicities and maximum tolerated dose (MTD) of intratumoral infusion of IL13-PE38QQR cytotoxin in patiens with recurrent supratentorial malignant glioma: a phase I/II study. Proc Am Soc Clin Oncol 2003; [abst. 405].
19. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65: 27-35.
20. Badruddoja MA, Reardon DA, Akabani G, Friedman AH, Friedman HS, Rich JN, et al. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. ASCO Annual Meeting, New Orleans. 2004; [abst. 1569].
21. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front Biosci 2003; 8: 115-27.